Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907854 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 407
- Enrollment target
NCT01907854: Completed Phase 4 study, sponsored by Novo Nordisk A/S.
NCT01907854 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 407 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01907854, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 407 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.
Primary Outcome
Change from baseline in HbA1c was analysed after 26 weeks of treatment. Analysis population set: full analysis set (FAS); all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using mixed model for repeated measurements (MMRM).
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2013-12-02 |
| Est. Completion | 2015-06-15 |
| Phase | Phase 4 |
What the finished NCT01907854 record still lists
NCT01907854 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01907854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01907854 about?
NCT01907854 is a clinical study titled "Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin". This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.
What is the current status of trial NCT01907854?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 407 participants. The study started on 2013-12-02. Estimated completion is 2015-06-15.
What interventions are being tested in trial NCT01907854?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01907854?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01907854's enrollment target sits among peer trials
407 208th of 2000 higher than 1,792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI